Akums Q4 PAT Drops 45.6% YoY to ₹81 Crore

Akums Drugs reported Q4 FY26 PAT of ₹81 crore, a 45.6% YoY decline, despite an 11.2% YoY rise in total income to ₹1,193 crore.
The company highlighted progress on a major 200 Mn Euro European CDMO contract, with supplies scheduled to commence from FY28 onwards.
A joint venture with the Zambian government was established for a $45 million project, including $25 million annual supply commitments for FY27-28.
Full-year FY26 revenue grew 5.8% YoY to ₹4,359 crore, with CDMO business contributing 80% of total revenue.